Le Lézard
Classified in: Health
Subjects: MAV, PDT, AVO, FVT

Media/Photo Advisory - MS From the Inside Out Virtual Reality Experience Comes to Montreal for One Day Only


The powerful and emotionally moving journey allows users to step into the world of someone living with MS

MONTREAL, May 21, 2019 /CNW/ - Canada has one of the highest rates of multiple sclerosis (MS) in the world, with an estimated 1 in 385 people living with the diseasei, however many Canadians do not understand its full impact. Virtual reality (VR) technology is facilitating a better understanding of the patient journey and creating deeper empathy for those living with MS.

EMD Serono, Canada is taking the MS from the Inside Out experience to Montreal this May, to raise awareness for the impact of the disease during MS Awareness Month. (CNW Group/EMD Serono, Canada)

To coincide with Multiple Sclerosis Awareness Month, EMD Serono, Canada is bringing the MS from the Inside Out VR experience to Montreal. It takes users on a multisensory journey inside the brain of someone living with MS, and breaks down the invisible aspects of the disease and the complex science and symptoms that go beyond mobility. Attendees will experience the unseen burdens that accompany MS to better understand how it affects those living with MS and their loved ones.

WHEN:

Monday, May 27, 2019
Media interviews: 11:00 a.m. to 1 p.m.
Public hours: 11:00 a.m. to 4:00 p.m.



WHERE:

Complexe Desjardins, La Grande-Place (near the fountain)

150, Sainte-Catherine St. W

Montreal, QC H2X 3Y2

 

WHO:

?

Gaby Murphy, Managing Director and General Manager, EMD Serono, Canada


?

Louis Adam, MS Society Executive Director, Quebec Division


?

Dr. Lisa Sabella, Neurologist, Clinique Neuro Rive-Sud



WHAT:

The MS from the Inside Out VR experience is helping bring the MS experience to life and raising awareness of the impact of the disease. Join us for an opportunity to experience the powerful and emotionally moving journey and learn more about MS.

 

About EMD Serono, Canada
EMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Ontario.

i

MS Society of Canada. What is MS. Accessed May 6, 2019. Available at https://mssociety.ca/about-ms/what-is-ms  

 

SOURCE EMD Serono, Canada


These press releases may also interest you

at 13:26
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...



News published on and distributed by: